Saturday, September 6, 2008 - 6:49PM EST

Review Articles

1. Topotecan in the management of cervical cancer.

Author
Randall-Whitis LM; Monk BJ;
Institution
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, 101 The City Dr South, Bldg 56, Suite 210, Orange, CA 92868, USA. lrandall@uci.edu
Journal
Expert Opin Pharmacother. 2007 Feb;8(2):227-36.
Abstract URL
Click here to view abstract

2. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer.

Author
Beiner ME; Covens A;
Institution
Gynecologic Oncology Division, University of Toronto, Toronto, ON, Canada.
Journal
Nat Clin Pract Oncol. 2007 Jun;4(6):353-61.
Abstract URL
Click here to view abstract

3. Management of metastatic cervical cancer: review of the literature.

Author
Long HJ 3rd;
Institution
Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN, USA. long.harry@mayo.edu
Journal
J Clin Oncol. 2007 Jul 10;25(20):2966-74.
Abstract URL
Click here to view abstract

4. Impact of the human papilloma vaccine on cervical cancer.

Author
Chan JK; Berek JS;
Institution
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford, CA 94305, USA.
Journal
J Clin Oncol. 2007 Jul 10;25(20):2975-82.
Abstract URL
Click here to view abstract

5. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review.

Author
van de Lande J; Torrenga B; Raijmakers PG; Hoekstra OS; van Baal MW; Brolmann HA; Verheijen RH;
Institution
Department of Obstetrics and Gynecology, Vrije Universiteit Medical Center, P.O. Box 7057, The Netherlands. j.vandelande@vumc.nl
Journal
Gynecol Oncol. 2007 Sep;106(3):604-13. Epub 2007 Jul 12.
Abstract URL
Click here to view abstract

6. Vaccines against human papillomavirus: perspectives for controlling cervical cancer.

Author
Garcia Carranca A; Galvan SC;
Institution
Laboratory of Virus and Cancer, Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico. carranca@biomedicas.unam.mx
Journal
Expert Rev Vaccines. 2007 Aug;6(4):497-510.
Abstract URL
Click here to view abstract

7. The development and future of oligonucleotide-based therapies for cervical cancer.

Author
Gu W; Putral LN; Irving A; McMillan NA;
Institution
University of Queensland, Diamantina Institute for Cancer, Immunology and Molecular Medicine, Cancer Biology Programme, Brisbane, QLD 4072, Australia.
Journal
Curr Opin Mol Ther. 2007 Apr;9(2):126-31.
Abstract URL
Click here to view abstract

8. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing.

Author
Wheeler CM;
Institution
Department of Molecular Genetics and Microbiology, University of New Mexico Health Sciences Center, House of Prevention Epidemiology, Building 191, 1816 Sigma Chi Road, Albuquerque, NM 87131, USA. cwheeler@salud.unm.edu
Journal
Nat Clin Pract Oncol. 2007 Apr;4(4):224-35.
Abstract URL
Click here to view abstract

9. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.

Author
Arbyn M; Dillner J;
Institution
Unit of Cancer Epidemiology, Scientific Institute of Public Health, Brussels, Belgium. marc.arbyn@iph.fgov.be
Journal
J Clin Virol. 2007 Mar;38(3):189-97. Epub 2007 Jan 25.
Abstract URL
Click here to view abstract

10. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer.

Author
Wu TC;
Institution
Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD 21231, USA. wutc@jhmi.edu
Journal
Eur J Immunol. 2007 Feb;37(2):310-4.
Abstract URL
Click here to view abstract
Pages: 1 2 3 4 5 6